Vincristine as salvage treatment for refractory thrombotic thrombocytopenic purpura

Division of Hematology, Cardarelli General Hospital, Naples, Italy.
Annals of Hematology (Impact Factor: 2.4). 12/1999; 78(11):521-3. DOI: 10.1007/s002770050549
Source: PubMed

ABSTRACT Vincristine (1.4 mg/m(2) on day 1, followed by 1 mg on days 4 and 7) was given to eight patients with thrombotic thrombocytopenic purpura (TTP) who were refractory to plasma exchange (n=4) or plasma infusion (n=4). Seven of eight patients (87%) achieved a complete response; one was refractory to treatment and died within a few weeks. After a median follow-up of 50 months, all responding patients are alive and well. Two patients relapsed and were successfully retreated with vincristine. Toxicity was mild, consisting of two episodes of leukopenia and one of autonomic neuropathy leading to paralytic ileus in a patient aged 70 years. We conclude that vincristine is highly effective in the treatment of patients suffering from refractory TTP, with negligible toxicity.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract - Abstract - Abstract - Abstract - Background. Vincristin is an important and fre- quently used chemoterapeutic drug in the treatment of ma- lignant lymphoproliferative disease. Among its side effects are well known bone marrow supression and polyneuropathia. But common physicians are not familiar with vincristine bowel peristaltics inhibitory effect. Patient and methods. This study presents 64-years old patient with acute lymphoblastic leukemia (ALL) who was treated with chemotherapy which included vincristine. Two weeks after the treatment started paralytic ileus developed which was la- ter sucessfully treated with laxatives and prokynetic drugs. Secondary causes for ileus development were excluded. Lite- rature data was reviewed and a higher incidence of paraly- tic ileus in vincristine treated patients was found, especially when they are given concomitant itraconazole. Our patient received concommitant itraconazole as a part of antifungal prophylaxis against invasive aspergillosis which is a perceived routine on hematological departments. Conclusions. Vincristine treated patients should be carefully observed regarding bowel peristaltics and obstipation. If ob- stipation or even paralytic ileus developes, we must stop vin- cristine therapy. All patients receiving vincristine must re- ceive fluconazol instead of itraconazol as a part of antifun- gal prophylaxis. Ključne besede: Ključne besede: Ključne besede: Ključne besede: Ključne besede: akutna limfoblastna levkemija; limfoproli- ferativna bolezen; vinkristin; itrakonazol; paralitični ileus Izvleček - Izvleček - Izvleček - Izvleček - Izvleček - Izhodišča. Vinkristin je nepogrešljiv citostatik pri zdravljenju malignih limfoproliferativnih bolezni. Med stran- skimi učinki zdravila sta dobro poznana njegov zaviralni učinek na kostni mozeg in polinevropatija. Navadno pa leče- či zdravniki prezremo njegov zaviralni učinek na črevesno peristaltiko. Bolnik in metode. Predstavljen je 64-letni bolnik z akutno lim- foblastno levkemijo (ALL), zdravljen s kombinirano kemote- rapijo, ki je vključevala tudi vinkristin. Dva tedna po začet- ku zdravljenja je prišlo do nastanka paralitičnega ileusa, ki se je razrešil po dolgotrajnem zdravljenju z odvajali in proki- netiki. S preiskavami smo izključili sekundarni vzrok za na- stanek ileusa. Ob pregledu literature smo ugotovili, da je inci- denca paralitičnega ileusa pri bolnikih, zdravljenih z vinkri- stinom, še posebej visoka, če hkrati prejemajo tudi itrakona- zol. Tudi v našem primeru je bolnik prejemal itrakonazol, ki ga na hematoloških oddelkih pogosto uporabljamo za prepre- čevanje glivičnih okužb, predvsem invazivne aspergiloze. Zaključki. Pri bolnikih, ki prejemajo vinkristin, moramo biti pozorni na pojav zaprtja. Če se pojavi zaprtje ali pa pride celo do nastanka paralitičnega ileusa, potem moramo prene- hati zdraviti z vinkristinom. Vsi bolniki, ki prejemajo vinkri- stin, naj kot protiglivično preventivno zdravljenje prejemajo flukonazol in ne itrakonazol.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Secondary dyserythropoiesis has been associated with vincristine administration in dogs. Evaluation of bone marrow aspirates for the presence of morphologic abnormalities in the erythroid lineage aids in the diagnosis. However, morphologic features of circulating erythroid precursors in these cases have not been described previously. The purpose of this report was to describe the cytologic features of dyserythropoiesis in peripheral blood and also bone marrow smears in a case series of dogs with immune-mediated thrombocytopenia (IMT) treated with vincristine sulfate. Nineteen dogs receiving vincristine for treatment of IMT were identified by retrospectively searching a computerized medical record system. There were 5 dogs that had dysplastic erythroid precursors in peripheral blood smears within 7 days of vincristine treatment. Two of those 5 dogs also had evidence for erythrodysplasia in modified Wright's-stained bone marrow smears obtained postvincristine administration. Morphologic changes included bizarre or inappropriate mitotic figures, abnormal nuclear configurations (fragmentation, elongation, indentation, and binucleation), atypical nuclear remnants (Howell-Jolly bodies), or nuclear and cytoplasmic asynchrony within the erythroid precursors. A brief review of the literature with discussion of the etiologies for dyserythropoiesis is provided. The dyserythropoiesis was clinically insignificant in all 5 cases and resolved. However, pathologists and clinicians should be aware of these potential findings to prevent misdiagnosis of other conditions.
    Veterinary Clinical Pathology 10/2013; 42(4). DOI:10.1111/vcp.12089 · 1.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Treatment of immune-mediated disease in dogs and cats continues to evolve as new therapies are introduced or adapted from human medicine. Glucocorticoids remain the first-line therapy for many of the immune-mediated or inflammatory diseases of cats and dogs. The focus of this article is to provide an update on some of the common immunosuppressive therapies used in small animal veterinary medicine. The goals of therapy are to induce disease remission through the inhibition of inflammation and the modulation of lymphocyte function.
    Veterinary Clinics of North America Small Animal Practice 09/2013; 43(5):1149-70. DOI:10.1016/j.cvsm.2013.04.009 · 1.04 Impact Factor